Capmatinib for advanced, EGFR wild type, c-Met amplified, non-small cell lung cancer – second or third line
NIHR HSRIC
Record ID 32016001025
English
Authors' recommendations:
Capmatinib is a new drug to treat non-small cell lung cancer. Non-small cell lung cancer is the most common type of lung cancer. It is often diagnosed late and is difficult to treat once it has spread to other parts of the body. Capmatinib is taken as a tablet and may offer a new treatment option for people whose cancer has returned after their previous treatments.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
http://www.hsric.nihr.ac.uk/topics/capmatinib-for-advanced-egfr-wild-type-c-met-amplified-non-small-cell-lung-cancer-second-or-third-line/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Benzamides
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Imidazoles
- Triazines
- Protein Kinase Inhibitors
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.